Cargando…
An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
In recent years, considerable progress has been made in increasing the knowledge of tumour biology and drug resistance mechanisms in urothelial cancer. Therapeutic strategies have significantly advanced with the introduction of novel approaches such as immune checkpoint inhibitors and Fibroblast Gro...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402760/ https://www.ncbi.nlm.nih.gov/pubmed/35953604 http://dx.doi.org/10.1007/s00280-022-04459-7 |